Intranasal COVID-19 vaccines: From bench to bed
A Alu, L Chen, H Lei, Y Wei, X Tian, X Wei - EBioMedicine, 2022 - thelancet.com
Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization.
However, vaccination today failed to prevent the virus infection through the upper respiratory …
However, vaccination today failed to prevent the virus infection through the upper respiratory …
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
Multiple vaccines have recently been developed, and almost all the countries are presently
vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 …
vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 …
An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection
PA van der Ley, A Zariri, E van Riet… - Frontiers in …, 2021 - frontiersin.org
The development of more effective, accessible, and easy to administer COVID-19 vaccines
next to the currently marketed mRNA, viral vector, and whole inactivated virus vaccines is …
next to the currently marketed mRNA, viral vector, and whole inactivated virus vaccines is …
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Abstract Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines
display a superior advantage because the nasal mucosa is often the initial site of infection …
display a superior advantage because the nasal mucosa is often the initial site of infection …
[HTML][HTML] Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic
D Miteva, M Peshevska-Sekulovska… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Based on mucosal immunization to promote both mucosal and systemic immune responses,
next-generation coronavirus disease 2019 (COVID-19) vaccines would be administered …
next-generation coronavirus disease 2019 (COVID-19) vaccines would be administered …
Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge
RG King, A Silva-Sanchez, JN Peel, D Botta… - Vaccines, 2021 - mdpi.com
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for
effective prophylactic vaccination to prevent the spread of severe acute respiratory …
effective prophylactic vaccination to prevent the spread of severe acute respiratory …
[HTML][HTML] Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
V Mouro, A Fischer - Mucosal immunology, 2022 - Elsevier
The development and deployment of vaccines against COVID-19 demonstrated major
successes in providing immunity and preventing severe disease and death. Yet SARS-CoV …
successes in providing immunity and preventing severe disease and death. Yet SARS-CoV …
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
M Tiboni, L Casettari, L Illum - International journal of pharmaceutics, 2021 - Elsevier
It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular
administration designed to produce humoral and cell mediated immune responses …
administration designed to produce humoral and cell mediated immune responses …
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
Despite remarkable progress in the development and authorization of vaccines against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to validate …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to validate …